Matches in SemOpenAlex for { <https://semopenalex.org/work/W2213089373> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2213089373 endingPage "5598" @default.
- W2213089373 startingPage "5598" @default.
- W2213089373 abstract "5598 Background: A randomized trial has demonstrated that concurrent CRT is superior to radiotherapy (RT) alone in advanced NPC (Intergroup 0099, J Clin Oncol 16:1310, 1998). Methods: Between October 1996 and October 2001, we treated 35 pts with NPC (stage I: 1, II: 12, III: 7, IV: 15) with 1 cycle of induction CTX (5-fluorouracil 1000 mg/m2 D1–4, cisplatin 20 mg/m2 D1–4) followed by concurrent CRT starting on day 22. CRT consisted of RT (7020 cGy at 180 cGy/day) with concurrent cisplatin 20 mg/m2 on D22–25, D43–46, and D64–67. Results: Based on post-treatment imaging, complete response (CR) was achieved in 33 pts (94%), partial response in 1 pt, and one pt demonstrated progressive disease. Among pts with CR, 11 pts recurred: 6 locoregional, 5 distant. Twelve pts died, 10 with recurrence or disease progression, 1 with radiation induced brain necrosis, and 1 from unknown cause. Four-year progression-free survival and overall survival of total pts were 59% and 64%, respectively, with 46 months median follow-up in survivors. Major toxicities were oral mucositis (grade 3 or 4: 20 pts), radiation dermatitis (grade 3: 11 pts), and leukopenia (grade 3: 6 pts). Furthermore, thirty-one patients (89%) experienced at least one type of otototoxicity: otitis media (27 pts), sensorineural and/or conductive hearing loss (21 pts), external otitis (7 pts), tinnitus (5 pts). Conclusions: The outcome of pts treated with this combined modality therapy appears to be comparable with that of Intergroup 0099 trial with high CR rate. In addition, ototoxicity seems to be a very frequent and clinically significant complication of CRT for NPC. No significant financial relationships to disclose." @default.
- W2213089373 created "2016-06-24" @default.
- W2213089373 creator A5011166922 @default.
- W2213089373 creator A5016040545 @default.
- W2213089373 creator A5020296602 @default.
- W2213089373 creator A5033218288 @default.
- W2213089373 creator A5038041478 @default.
- W2213089373 creator A5047372729 @default.
- W2213089373 creator A5089068543 @default.
- W2213089373 creator A5089603377 @default.
- W2213089373 date "2004-07-15" @default.
- W2213089373 modified "2023-09-28" @default.
- W2213089373 title "Induction chemotherapy (CTX) followed by concurrent chemoradiotherapy (CRT) in patients (pts) with nasopharyngeal cancer (NPC)" @default.
- W2213089373 doi "https://doi.org/10.1200/jco.2004.22.90140.5598" @default.
- W2213089373 hasPublicationYear "2004" @default.
- W2213089373 type Work @default.
- W2213089373 sameAs 2213089373 @default.
- W2213089373 citedByCount "0" @default.
- W2213089373 crossrefType "journal-article" @default.
- W2213089373 hasAuthorship W2213089373A5011166922 @default.
- W2213089373 hasAuthorship W2213089373A5016040545 @default.
- W2213089373 hasAuthorship W2213089373A5020296602 @default.
- W2213089373 hasAuthorship W2213089373A5033218288 @default.
- W2213089373 hasAuthorship W2213089373A5038041478 @default.
- W2213089373 hasAuthorship W2213089373A5047372729 @default.
- W2213089373 hasAuthorship W2213089373A5089068543 @default.
- W2213089373 hasAuthorship W2213089373A5089603377 @default.
- W2213089373 hasConcept C126322002 @default.
- W2213089373 hasConcept C143998085 @default.
- W2213089373 hasConcept C2776611710 @default.
- W2213089373 hasConcept C2776694085 @default.
- W2213089373 hasConcept C2778424827 @default.
- W2213089373 hasConcept C2778997737 @default.
- W2213089373 hasConcept C2992261824 @default.
- W2213089373 hasConcept C509974204 @default.
- W2213089373 hasConcept C71924100 @default.
- W2213089373 hasConceptScore W2213089373C126322002 @default.
- W2213089373 hasConceptScore W2213089373C143998085 @default.
- W2213089373 hasConceptScore W2213089373C2776611710 @default.
- W2213089373 hasConceptScore W2213089373C2776694085 @default.
- W2213089373 hasConceptScore W2213089373C2778424827 @default.
- W2213089373 hasConceptScore W2213089373C2778997737 @default.
- W2213089373 hasConceptScore W2213089373C2992261824 @default.
- W2213089373 hasConceptScore W2213089373C509974204 @default.
- W2213089373 hasConceptScore W2213089373C71924100 @default.
- W2213089373 hasIssue "14_suppl" @default.
- W2213089373 hasLocation W22130893731 @default.
- W2213089373 hasOpenAccess W2213089373 @default.
- W2213089373 hasPrimaryLocation W22130893731 @default.
- W2213089373 hasRelatedWork W2288867969 @default.
- W2213089373 hasRelatedWork W2362517708 @default.
- W2213089373 hasRelatedWork W2371613422 @default.
- W2213089373 hasRelatedWork W2390066975 @default.
- W2213089373 hasRelatedWork W2393085443 @default.
- W2213089373 hasRelatedWork W2779421078 @default.
- W2213089373 hasRelatedWork W2883587006 @default.
- W2213089373 hasRelatedWork W2997709950 @default.
- W2213089373 hasRelatedWork W3184725279 @default.
- W2213089373 hasRelatedWork W4247921938 @default.
- W2213089373 hasVolume "22" @default.
- W2213089373 isParatext "false" @default.
- W2213089373 isRetracted "false" @default.
- W2213089373 magId "2213089373" @default.
- W2213089373 workType "article" @default.